In an exploratory analysis of the ARCADIA randomized clinical trial, hypertension with high‑risk features was associated with modification of antithrombotic treatment effects after cryptogenic stroke. Among patients without high‑risk hypertension features, apixaban was associated with a lower risk of recurrent ischemic stroke or systemic embolism compared with aspirin.

This secondary analysis of a randomized clinical trial evaluates the association between hypertension with high-risk features and treatment effect.